OLEMA PHARMACEUTICALS INC. - COMMON STOCK

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

11 май 2023 07:43:20 Источник Nasdaq GlobeNewswire

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 май 2023 15:01:03 Источник Nasdaq GlobeNewswire

Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress

08 май 2023 06:06:10 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 май 2023 15:30:57 Источник Nasdaq GlobeNewswire

Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

13 апр 2023 15:30:48 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 апр 2023 15:30:50 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update

09 мар 2023 15:00:17 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 мар 2023 16:00:11 Источник Nasdaq GlobeNewswire

Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference

02 мар 2023 15:05:19 Источник Nasdaq GlobeNewswire

Olema Oncology to Participate at Upcoming Investor Conferences

21 фев 2023 15:30:35 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 фев 2023 17:00:40 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 янв 2023 15:30:01 Источник Nasdaq GlobeNewswire

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 06:00:58 Источник Nasdaq GlobeNewswire

Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study

07 дек 2022 14:37:49 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 дек 2022 15:30:00 Источник Nasdaq GlobeNewswire

Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)

21 ноя 2022 08:16:07 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 ноя 2022 15:30:00 Источник Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 ноя 2022 15:30:00 Источник Nasdaq GlobeNewswire

Olema Oncology to Present at Upcoming Investor Conferences in November

01 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

26 окт 2022 02:00:00 Источник Nasdaq GlobeNewswire